BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11253252)

  • 1. The electrocardiographic QT interval and its prolongation in response to medications: differences between men and women.
    Schwartz JB
    J Gend Specif Med; 2000; 3(5):25-8. PubMed ID: 11253252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater quinidine-induced QTc interval prolongation in women.
    Benton RE; Sale M; Flockhart DA; Woosley RL
    Clin Pharmacol Ther; 2000 Apr; 67(4):413-8. PubMed ID: 10801251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.
    Fatti LM; Scacchi M; Lavezzi E; Pecori Giraldi F; De Martin M; Toja P; Michailidis G; Stramba-Badiale M; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):626-30. PubMed ID: 17054464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender differences in autonomic modulation of ventricular repolarization in humans.
    Nakagawa M; Ooie T; Ou B; Ichinose M; Takahashi N; Hara M; Yonemochi H; Saikawa T
    J Cardiovasc Electrophysiol; 2005 Mar; 16(3):278-84. PubMed ID: 15817086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs for men and women - how important is gender as a risk factor for TdP?
    Coker SJ
    Pharmacol Ther; 2008 Aug; 119(2):186-94. PubMed ID: 18472167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of corrected QT and corrected JT interval for incident coronary heart disease in a general population sample stratified by presence or absence of wide QRS complex: the ARIC Study with 13 years of follow-up.
    Crow RS; Hannan PJ; Folsom AR
    Circulation; 2003 Oct; 108(16):1985-9. PubMed ID: 14517173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of prolonged QT interval duration in male patients with Cushing's disease.
    Pecori Giraldi F; Toja PM; Michailidis G; Metinidou A; De Martin M; Scacchi M; Stramba-Badiale M; Cavagnini F
    Exp Clin Endocrinol Diabetes; 2011 Apr; 119(4):221-4. PubMed ID: 21374543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidences of the gender-related differences in cardiac repolarization and the underlying mechanisms in different animal species and human.
    Cheng J
    Fundam Clin Pharmacol; 2006 Feb; 20(1):1-8. PubMed ID: 16448390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Proarrhythmic (torsadogenic) effects of QT-prolonging non-antiarrhythmic drugs].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Mar; 146(10):451-60. PubMed ID: 15835343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in understanding sex differences in cardiac repolarization.
    James AF; Choisy SC; Hancox JC
    Prog Biophys Mol Biol; 2007 Jul; 94(3):265-319. PubMed ID: 15979693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of QT interval in patients treated with psychotropic drugs.
    Novotny T; Florianova A; Ceskova E; Weislamplova M; Palensky V; Tomanova J; Sisakova M; Toman O; Spinar J
    Int J Cardiol; 2007 May; 117(3):329-32. PubMed ID: 16863665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
    Vieweg WV
    J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.